ERBB2 and breast carcinoma: Two automated image analysis methods, i.e. DEPArray and ACCEPT, were used to measure HER-2 IF signal on CellSearch-enriched samples of eight breast cancer cell lines with incremental HER-2-FITC intensity, categorized as HER-2neg (MCF-7, MDA-MB-436, and BT-20), HER-2med (MDA-MB-453), and HER-2high (KPL-4, SUM190, IBC-3, and SKBR-3) according to literature [8, 9, 13] (Fig 3A and 3B).